Status:

TERMINATED

Effect of Increlex® on Children With Crohn Disease

Lead Sponsor:

Nationwide Children's Hospital

Collaborating Sponsors:

Tercica

Conditions:

Crohn Disease

Eligibility:

All Genders

5-15 years

Phase:

PHASE2

PHASE3

Brief Summary

Patients with Crohn disease often have poor weight gain and short stature, yet the etiology of the poor growth is not well defined. Studies in chronically ill patients who do not have Crohn disease ha...

Detailed Description

1. Subjects. We will recruit 20 established Crohn patients from our gastroenterology (GI) referral practice at Nationwide Children's Hospital in Columbus, Ohio. Each will have previously undergone a c...

Eligibility Criteria

Inclusion

  • Moderate to severe Crohn Disease (PCDAI \> 30)
  • Chronological age 5-15 years old
  • Tanner 1 - 3
  • Bone age less than or equal to 13 in females and 14 in males

Exclusion

  • Identified infectious etiology
  • Immunological disorder (excluding Crohn disease)
  • Associated severe concomitant chronic illnesses (CF, liver failure, etc)

Key Trial Info

Start Date :

October 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2010

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT00764699

Start Date

October 1 2008

End Date

May 1 2010

Last Update

March 2 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Nationwide Children's Hospital

Columbus, Ohio, United States, 43205

Effect of Increlex® on Children With Crohn Disease | DecenTrialz